NCCN 7th Annual Congress: Hematologic Malignancies

 
 
 

 

Improving stem cell collection

Mark Fuerst Read Article
Published: 10/02/12

Bensinger_William_MD_240.jpg
William Bensinger, MD

Some patients are simply more likely than others to experience poor stem cell mobilization. But there are a variety of ways in which clinicians can improve stem cell collection and enhance engraftment, according to a speaker at the NCCN 7th Annual Congress on Hematologic Malignancies. “You cannot change a patient’s age, disease, or stage, but you can mobilize and collect early in the disease course and avoid marrow-toxic drugs,” said William Bensinger, MD, of the Fred Hutchinson Cancer . . . [Read Article]

Lenalidomide still best maintenance for MM, studies suggest

Mark Fuerst Read Article
Published: 09/29/12

multiple_myeloma_bone_marrow_aspirate_showing_230.jpg
Bone marrow aspirate
showing multiple myeloma

Results of several studies suggest that lenalidomide remains the best option for maintenance in patients with multiple myeloma. George Somlo, MD, of the City of Hope Comprehensive Cancer Center, discussed these studies at the NCCN 7th Annual Congress on Hematologic Malignancies, which took place September 14-15. Dr Somlo noted that a number of phase 3 studies have shown that lenalidomide maintenance elicits higher response rates in patients who receive melphalan . . . [Read Article]

Where MM treatment falls short

Mark Fuerst Read Article
Published: 09/25/12

Anderson_Kenneth_MD_headshot_240_v2.jpg
Kenneth Anderson, MD

Patients with multiple myeloma (MM) are living longer than ever before, but there is still room to improve their treatment, according to a speaker at the NNCN 7th Annual Congress on Hematologic Malignancies. Kenneth Anderson, MD, of the Dana-Farber Cancer Institute in Boston, said we need to better predict patient responses, find new ways to prevent relapse, and determine the optimal induction regimen for transplant-eligible patients. However, he also pointed out that . . . [Read Article]

Speaker offers guidance for treating relapsed/refractory ALL

Erilyn Riley Read Article
Published: 09/22/12

Alvarnas_Joseph C_MD_240.jpg
Joseph C. Alvarnas, MD

Timely hematopoietic stem cell transplant (HSCT) and more effective novel agents are the keys to improving treatment of relapsed/refractory acute lymphoblastic leukemia (ALL), according to an expert. Joseph C. Alvarnas, MD, of City of Hope Comprehensive Cancer Center in California, presented this viewpoint at the NCCN 7th Annual Congress on Hematologic Malignancies, which took place September 14-15. Dr Alvarnas emphasized the importance of early risk stratification. [Read Article]

Recognizing suboptimal response in CML

Erilyn Riley Read Article
Published: 09/21/12

Shah_Neil P_MD_PhD.jpg
Neil P. Shah, MD, PhD

Recognizing and reacting to suboptimal response in chronic myelogenous leukemia (CML) in the age of second-generation tyrosine kinase inhibitors (TKIs) can be complicated, especially when it’s not really clear anymore what suboptimal response is. Neil P. Shah, MD, PhD, of the University of California, San Francisco, explained how the NCCN is interpreting suboptimal response in CML and reviewed what’s new in the guidelines at the . . . [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}